Indevus Acquired – Take the $$$ – Analyst Blog
Source: http://www.zacks.com/stock/news/16710/Indevus+Acquired+-+Take+the+%24%24%24+-+Analyst+BlogPosted on Thursday, January 8th, 2009 | In Stocks to Watch
Just two short weeks ago, we initiated coverage of Indevus Pharmaceuticals (IDEV) with a Buy rating and $6 price target. Paramount to our investment thesis was the eventual approval of Nebido in late calendar 2009.
We were encouraged by the fact that management has come to an agreement with the FDA on the re-filing of the Nebido NDA, and believed that approval will be a transformational event for Indevus. We were also bullish on the rest of the pipeline.
Endo Pharmaceuticals (ENDP) must agree, having just signed a definitive merger agreement with Indevus worth up to $7.50 per share to Indevus shareholders. We are advising clients to take the money as such, our rating is now Hold.
Read the full analyst report on IDEV
“IDEV” Free Stock Analysis: Buy? Sell? Hold?
“ENDP” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Dress Barn Tops, Lifts Outlook - Analyst Blog - November 23rd, 2009
- Another Price Cut for Palm - Analyst Blog - November 23rd, 2009
- Ford Focuses on Brazil - Analyst Blog - November 23rd, 2009
- Ratings Action on Assurant - Analyst Blog - November 23rd, 2009
- Sands China Raises $2.5B in IPO - Analyst Blog - November 23rd, 2009
Blog, Endo Pharmaceuticals, Fda, Indevus Pharmaceuticals;, Stocks to Watch, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.